Of the 65 patients with ALK-positve NSCLC who underwent treatment failure of crizotinib, 43 (66.2%) received alectinib and 22 (33.8%) received ceritinib as the subsequent treatment. The gene discussed is ALK; the disease is non-small cell lung carcinoma.